Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Seroreactivity to Cutaneous Human Papillomaviruses among Patients with Nonmelanoma Skin Cancer or Benign Skin Lesions.

Andersson, Kristin LU ; Waterboer, Tim ; Kirnbauer, Reinhard ; Slupetzky, Katharina ; Iftner, Thomas ; de Villiers, Ethel-Michele ; Forslund, Ola LU ; Pawlita, Michael and Dillner, Joakim LU (2008) In Cancer Epidemiology Biomarkers & Prevention 17(1). p.189-195
Abstract
Cutaneous human papillomaviruses (HPV) are common in nonmelanoma skin cancers, benign skin lesions, and healthy skin. Increased seroprevalences for cutaneous HPV among nonmelanoma skin cancer patients have been described. To determine whether antibodies to cutaneous HPV are related to presence of the virus and/or to skin disease, we collected serum and biopsies from both lesions and healthy skin from 434 nonimmunosuppressed patients (72 squamous cell carcinomas, 160 basal cell carcinomas, 81 actinic keratoses, and 121 benign lesions). Biopsies were analyzed for HPV DNA by PCR, cloning, and sequencing. Serum antibodies to the major capsid protein L1 of HPV 1, 5, 6, 8, 9, 10, 15, 16, 20, 24, 32, 36, 38, and 57 as well as to the oncoproteins... (More)
Cutaneous human papillomaviruses (HPV) are common in nonmelanoma skin cancers, benign skin lesions, and healthy skin. Increased seroprevalences for cutaneous HPV among nonmelanoma skin cancer patients have been described. To determine whether antibodies to cutaneous HPV are related to presence of the virus and/or to skin disease, we collected serum and biopsies from both lesions and healthy skin from 434 nonimmunosuppressed patients (72 squamous cell carcinomas, 160 basal cell carcinomas, 81 actinic keratoses, and 121 benign lesions). Biopsies were analyzed for HPV DNA by PCR, cloning, and sequencing. Serum antibodies to the major capsid protein L1 of HPV 1, 5, 6, 8, 9, 10, 15, 16, 20, 24, 32, 36, 38, and 57 as well as to the oncoproteins E6 and E7 of HPV 8 and 38 were detected using a multiplexed fluorescent bead-based assay. Type-specific seroprevalence among patients with the same type of HPV DNA (sensitivity of serology) varied from 0% to at most 28%. Presence of HPV DNA and antibodies to the same HPV type was not significantly correlated. However, seropositivity to any HPV type was significantly more common among patients positive for HPV DNA of any HPV type (odds ratio, 1.90; 95% confidence interval, 1.55-2.34). Seroprevalences were similar among the different patient groups but was, for most HPV types, somewhat higher among squamous cell carcinoma patients than among basal cell carcinoma patients (P < 0.01). In conclusion, additional studies are required to clarify the biological meaning of seropositivity as a marker of cutaneous HPV infection and skin disease. (Cancer Epidemiol Biomarkers Prev 2008;17(1):189-95). (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Epidemiology Biomarkers & Prevention
volume
17
issue
1
pages
189 - 195
publisher
American Association for Cancer Research
external identifiers
  • pmid:18199724
  • wos:000252503900024
  • scopus:38849152772
ISSN
1538-7755
DOI
10.1158/1055-9965.EPI-07-0405
language
English
LU publication?
yes
id
9e3e8e14-e41b-408f-9dd1-73b8039dd50c (old id 1021326)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18199724?dopt=Abstract
date added to LUP
2016-04-04 09:08:59
date last changed
2022-05-01 08:11:37
@article{9e3e8e14-e41b-408f-9dd1-73b8039dd50c,
  abstract     = {{Cutaneous human papillomaviruses (HPV) are common in nonmelanoma skin cancers, benign skin lesions, and healthy skin. Increased seroprevalences for cutaneous HPV among nonmelanoma skin cancer patients have been described. To determine whether antibodies to cutaneous HPV are related to presence of the virus and/or to skin disease, we collected serum and biopsies from both lesions and healthy skin from 434 nonimmunosuppressed patients (72 squamous cell carcinomas, 160 basal cell carcinomas, 81 actinic keratoses, and 121 benign lesions). Biopsies were analyzed for HPV DNA by PCR, cloning, and sequencing. Serum antibodies to the major capsid protein L1 of HPV 1, 5, 6, 8, 9, 10, 15, 16, 20, 24, 32, 36, 38, and 57 as well as to the oncoproteins E6 and E7 of HPV 8 and 38 were detected using a multiplexed fluorescent bead-based assay. Type-specific seroprevalence among patients with the same type of HPV DNA (sensitivity of serology) varied from 0% to at most 28%. Presence of HPV DNA and antibodies to the same HPV type was not significantly correlated. However, seropositivity to any HPV type was significantly more common among patients positive for HPV DNA of any HPV type (odds ratio, 1.90; 95% confidence interval, 1.55-2.34). Seroprevalences were similar among the different patient groups but was, for most HPV types, somewhat higher among squamous cell carcinoma patients than among basal cell carcinoma patients (P &lt; 0.01). In conclusion, additional studies are required to clarify the biological meaning of seropositivity as a marker of cutaneous HPV infection and skin disease. (Cancer Epidemiol Biomarkers Prev 2008;17(1):189-95).}},
  author       = {{Andersson, Kristin and Waterboer, Tim and Kirnbauer, Reinhard and Slupetzky, Katharina and Iftner, Thomas and de Villiers, Ethel-Michele and Forslund, Ola and Pawlita, Michael and Dillner, Joakim}},
  issn         = {{1538-7755}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{189--195}},
  publisher    = {{American Association for Cancer Research}},
  series       = {{Cancer Epidemiology Biomarkers & Prevention}},
  title        = {{Seroreactivity to Cutaneous Human Papillomaviruses among Patients with Nonmelanoma Skin Cancer or Benign Skin Lesions.}},
  url          = {{http://dx.doi.org/10.1158/1055-9965.EPI-07-0405}},
  doi          = {{10.1158/1055-9965.EPI-07-0405}},
  volume       = {{17}},
  year         = {{2008}},
}